Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
Date:10/11/2011

PARSIPPANY, N.J., Oct. 11, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that new data highlighting the pain control and pharmacokinetic properties of EXPAREL™ (bupivacaine liposome extended-release injectable suspension), the company's lead investigational product for postsurgical pain management, will be presented during poster presentations at the 2011 Annual Meetings of the American Society of Anesthesiologists (ASA) and the American College of Clinical Pharmacy (ACCP) in Chicago and Pittsburgh, respectively.

Currently under review with the U.S. Food and Drug Administration, EXPAREL is an innovative long-acting bupivacaine that has been shown in multiple Phase 2 and Phase 3 clinical studies to provide prolonged postsurgical analgesia for up to 72 hours with a single-dose local administration at the surgical site. The drug combines bupivacaine with DepoFoam®, Pacira's proven product delivery technology that delivers medication over a desired time period.

"We have continued to execute on our strategy to present EXPAREL clinical data to key medical audiences and we are pleased that these data will be showcased at these important medical meetings," said Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "We look forward to sharing new comparative data highlighting the pain control advantages that EXPAREL offers, as well as pharmacokinetic data, with the pharmacy and anesthesiology communities, who we believe will find great utility in EXPAREL should it be approved later this year."

The schedule for Pacira poster presentations at ASA in Chicago is as follows:

Poster Title: Comparison of Immediate-Release Bupivacaine vs EXPAREL™ (Bupivacaine Liposome Extended-Release Injectable Suspension) on Opioid Requirements and Related
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
11. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
(Date:12/15/2014)... 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" ... of crop seeds in China , today ... year 2014 ended September 30, 2014, before the market opens ... host a teleconference on January 8, 2015, at 8:00 a.m. ... to discuss the results. To participate in the call, please ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... Chairman of Audit committee, TUSTIN, Calif., Nov. 5 ... announced today Mr. Douglas MacLellan has been elected by,its ... Officer and Executive,Chairman effective immediately. Mr. Michael Boswell has ... former role as Chairman of AMDL,s,Audit committee and long-standing ...
... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... & Renshaw 10th Annual Healthcare Conference on,Tuesday, November ... will be held at,the New York Palace Hotel ... about this conference, please visit:, http://www.rodmanandrenshaw.com/conferences?id=19 , ...
... Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC Bulletin Board: ... pumps and associated clinical services,today announced financial results ... ended September 30, 2008., Mr. Steve Watkins, ... a solid 14.5% increase in revenue for the ...
Cached Biology Technology:AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 2AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 3AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Resveratrol, a compound in grapes, displays antioxidant and ... researchers at the UT Health Science Center San Antonio ... beneficial health effects. Resveratrol stimulates the expression of ... store fat, the team found. Adiponectin has a wide ...
... The bacterium which causes acne (Propionibacterium acnes) will be the ... Peter Lambert of Aston University. As well as acne, this ... is often ignored at diagnosis. Why are we not more ... length of stomach upsets and boost the immune system: , ...
... study that relates global energy use to economic growth, ... finds strong correlations between these two measures both among ... the study,s authors to infer that energy use limits ... in energy supply will be required to meet the ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2Probiotics, prebiotics and biofuel-producing bacteria 2Study finds energy limits global economic growth 2
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... standard of the Axima range, the ... mass accuracy, resolution, sensitivity and mass ... both linear and reflectron time-of-flight analysis. ... enables the generation of seamless PSD, ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... for use with a wide range of ... water and some of the higher boiling ... removing water and organic solvents from a ... vials and round bottom flasks; making it ...
Biology Products: